Project Details
Description
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for Participants with Newly Diagnosed AML Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemo
| Short title | Camelot-2 |
|---|---|
| Status | Active |
| Effective start/end date | 01.12.2025 → 31.12.2029 |
Fields of science
- 302024 Haematology
- 302055 Oncology
- 303 Health Sciences
- 304 Medical Biotechnology
- 305 Other Human Medicine, Health Sciences
- 302 Clinical Medicine
- 301 Medical-Theoretical Sciences, Pharmacy